Literature DB >> 29880307

Precision medicine in KCNJ11 permanent neonatal diabetes.

Siri Atma W Greeley1, Lisa R Letourneau1, Louis H Philipson2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29880307      PMCID： PMC6345272          DOI： 10.1016/S2213-8587(18)30138-4

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  15 in total

1.  Modern Sulfonylureas: Dangerous or Wrongly Accused?

Authors:  Matthew C Riddle
Journal:  Diabetes Care       Date:  2017-05       Impact factor: 19.112

2.  Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes: Mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures.

Authors:  Monica S Lanning; David Carmody; Łukasz Szczerbiński; Lisa R Letourneau; Rochelle N Naylor; Siri Atma W Greeley
Journal:  Pediatr Diabetes       Date:  2017-12-05       Impact factor: 4.866

3.  Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.

Authors:  Wojciech Mlynarski; Andrei I Tarasov; Agnieszka Gach; Christophe A Girard; Iwona Pietrzak; Lejla Zubcevic; Jacek Kusmierek; Tomasz Klupa; Maciej T Malecki; Frances M Ashcroft
Journal:  Nat Clin Pract Neurol       Date:  2007-11

4.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

Authors:  Anna L Gloyn; Ewan R Pearson; Jennifer F Antcliff; Peter Proks; G Jan Bruining; Annabelle S Slingerland; Neville Howard; Shubha Srinivasan; José M C L Silva; Janne Molnes; Emma L Edghill; Timothy M Frayling; I Karen Temple; Deborah Mackay; Julian P H Shield; Zdenek Sumnik; Adrian van Rhijn; Jerry K H Wales; Penelope Clark; Shaun Gorman; Javier Aisenberg; Sian Ellard; Pål R Njølstad; Frances M Ashcroft; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

5.  Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected].

Authors:  Kanetee Busiah; Séverine Drunat; Laurence Vaivre-Douret; Amélie Bonnefond; Albane Simon; Isabelle Flechtner; Bénédicte Gérard; Nathalie Pouvreau; Caroline Elie; Revital Nimri; Liat De Vries; Nadia Tubiana-Rufi; Chantal Metz; Anne-Marie Bertrand; Sylvie Nivot-Adamiak; Marc de Kerdanet; Chantal Stuckens; Farida Jennane; Pierre-François Souchon; Claire Le Tallec; Christelle Désirée; Sabrina Pereira; Aurélie Dechaume; Jean-Jacques Robert; Moshe Phillip; Raphaël Scharfmann; Paul Czernichow; Philippe Froguel; Martine Vaxillaire; Michel Polak; Hélène Cavé
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-06       Impact factor: 32.069

6.  The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.

Authors:  Marco Tuccori; Jennifer W Wu; Hui Yin; Agnieszka Majdan; Laurent Azoulay
Journal:  Diabetes Care       Date:  2015-09-04       Impact factor: 19.112

7.  The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes.

Authors:  Siri Atma W Greeley; Priya M John; Aaron N Winn; Joseph Ornelas; Rebecca B Lipton; Louis H Philipson; Graeme I Bell; Elbert S Huang
Journal:  Diabetes Care       Date:  2011-01-27       Impact factor: 19.112

8.  Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.

Authors:  Pamela Bowman; Åsta Sulen; Fabrizio Barbetti; Jacques Beltrand; Pernille Svalastoga; Ethel Codner; Ellen H Tessmann; Petur B Juliusson; Torild Skrivarhaug; Ewan R Pearson; Sarah E Flanagan; Tarig Babiker; Nicholas J Thomas; Maggie H Shepherd; Sian Ellard; Iwar Klimes; Magdalena Szopa; Michel Polak; Dario Iafusco; Andrew T Hattersley; Pål R Njølstad
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-04       Impact factor: 32.069

9.  Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents.

Authors:  Carolina Lahmann; Holger B Kramer; Frances M Ashcroft
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

10.  Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion.

Authors:  Wojciech Fendler; Iwona Pietrzak; Melissa F Brereton; Carolina Lahmann; Mariusz Gadzicki; Malgorzata Bienkiewicz; Izabela Drozdz; Maciej Borowiec; Maciej T Malecki; Frances M Ashcroft; Wojciech M Mlynarski
Journal:  Diabetes Care       Date:  2013-03-05       Impact factor: 19.112
View more
  2 in total

1.  KCNJ11 and KCNQ1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes Mellitus.

Authors:  Sandra Majcher; Przemysław Ustianowski; Damian Malinowski; Michał Czerewaty; Maciej Tarnowski; Krzysztof Safranow; Violetta Dziedziejko; Andrzej Pawlik
Journal:  Genes (Basel)       Date:  2022-07-23       Impact factor: 4.141

2.  A new mutation c.685G>A:p.E229K in the KCNJ11 gene: A case report of maturity-onset diabetes of the young13.

Authors:  Xinjie Song; Yonghong Cao; Jun Ye; Wu Dai; Suwan Zhang; Shuai Ye
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.